GSK, Amira sign $425M licensing pact

GlaxoSmithKline has agreed to pay Amira Pharmaceuticals up to $425 million for the exclusive worldwide rights to its FLAP inhibitors, including AM103 and other compounds within the current development program. Glaxo will first focus on AM103, an experimental asthma therapy that has successfully completed a Phase I trial. 

"With their experience and expertise in this area we hope that AM103 will become the first FLAP inhibitor available to patients worldwide to treat symptoms of asthma and possibly other inflammatory diseases," says Peppi Prasit, CSO and co-founder of Amira.

- check out the release for more info

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.